The estimated Net Worth of Hafrun Fridriksdottir is at least $6.89 million dollars as of 17 May 2022. Hafrun Fridriksdottir owns over 130,000 units of Teva- Pharmaceutical Industries stock worth over $24,893 and over the last 12 years he sold TEVA stock worth over $2,489,961. In addition, he makes $4,377,720 as Executive Vice President - Global R&D at Teva- Pharmaceutical Industries.
Hafrun has made over 16 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 130,000 units of TEVA stock worth $1,068,600 on 17 May 2022.
The largest trade he's ever made was selling 130,000 units of Teva- Pharmaceutical Industries stock on 17 May 2022 worth over $1,068,600. On average, Hafrun trades about 17,642 units every 30 days since 2012. As of 17 May 2022 he still owns at least 1,386 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Hafrun Fridriksdottir stock trades at the bottom of the page.
Dr. Hafrun Fridriksdottir serves as Executive Vice President - Global R&D of the Company. From February 2017 to November 2017, she served as Executive Vice President, President of Global Generics R&D, after serving as Senior Vice President and President of Global Generics R&D from 2016. Prior to joining Teva, from 2015 to 2016, Dr. Fridriksdottir served as Senior Vice President and President of Global Generics R&D in Allergan plc. From 2002 to 2015, she held positions of increasing responsibility within the Actavis Group, including Senior Vice President, R&D. From 1997 to 2002, Dr. Fridriksdottir served as Divisional Manager of Development at Omega Pharma, until its merger with Actavis. Dr. Fridriksdottir received an MS degree in pharmacy and a Ph.D. in physical pharmacy from the University of Iceland.
As the Executive Vice President - Global R&D of Teva- Pharmaceutical Industries, the total compensation of Hafrun Fridriksdottir at Teva- Pharmaceutical Industries is $4,377,720. There are 3 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Hafrun Fridriksdottir is 58, he's been the Executive Vice President - Global R&D of Teva- Pharmaceutical Industries since 2017. There are 11 older and 16 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Hafrun's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks et Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: